Viking Therapeutics is a thoroughly American biopharmaceutical enterprise, incorporated under the laws of the United States and headquartered in San Diego, California. As a publicly traded clinical-stage corporation listed on the NASDAQ exchange, it focuses on developing novel therapeutics for metabolic and endocrine diseases. Its entire executive leadership, core laboratory operations, and clinical trial coordination are managed domestically within the United States framework.